342 related articles for article (PubMed ID: 28872889)
1. Association Between the Lower Extremity Deep Venous Thrombosis, the Warfarin Maintenance Dose, and CYP2C9*3, CYP2D6*10, and CYP3A5*3 Genetic Polymorphisms: A Case-Control Study.
Ju S; Gao Y; Cao X; Zhang XF; Yan CC; Liu FT
Genet Test Mol Biomarkers; 2017 Sep; 21(9):539-546. PubMed ID: 28872889
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
3. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
4. Analysis of CYP2C9 polymorphisms (*2 and *3) in warfarin therapy patients in Pakistan. Association of CYP2C9 polymorphisms (*2 and*3) with warfarin dose, age, PT and INR.
Yasmeen F; Ghafoor MB; Khalid AW; Latif W; Mohsin S; Khaliq S
J Thromb Thrombolysis; 2015 Aug; 40(2):218-24. PubMed ID: 25904339
[TBL] [Abstract][Full Text] [Related]
5. Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
Fereidouni M; Moossavi M; Kazemi T; Nouranihassankiade S; Asghari A
J Cell Biochem; 2019 Jun; 120(6):9588-9593. PubMed ID: 30525241
[TBL] [Abstract][Full Text] [Related]
6. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
9. Association between genetic polymorphisms of CYP2C9 and VKORC1 and safety and efficacy of warfarin: Results of a 5 years audit.
Biswas M; Bendkhale SR; Deshpande SP; Thaker SJ; Kulkarni DV; Bhatia SJ; Rajadhyaksha AG; Gogtay NJ; Thatte UM
Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S13-S19. PubMed ID: 30595245
[TBL] [Abstract][Full Text] [Related]
10. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
An SH; Lee KE; Chang BC; Gwak HS
J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
[TBL] [Abstract][Full Text] [Related]
11. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
[TBL] [Abstract][Full Text] [Related]
12. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk.
Ivashchenko D; Rusin I; Sychev D; Grachev A
Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991
[TBL] [Abstract][Full Text] [Related]
13. CYP2C9 genotypes and the quality of anticoagulation control with warfarin therapy among Brazilian patients.
Lima MV; Ribeiro GS; Mesquita ET; Victer PR; Vianna-Jorge R
Eur J Clin Pharmacol; 2008 Jan; 64(1):9-15. PubMed ID: 17955230
[TBL] [Abstract][Full Text] [Related]
14. Influence of CYP2C9 polymorphism and phenytoin co-administration on acenocoumarol dose in patients with cerebral venous thrombosis.
De T; Christopher R; Nagaraja D
Thromb Res; 2014 May; 133(5):729-35. PubMed ID: 24530212
[TBL] [Abstract][Full Text] [Related]
15. Correlations of CYP2C9*3/CYP2D6*10/CYP3A5*3 gene polymorphisms with efficacy of etanercept treatment for patients with ankylosing spondylitis: A case-control study.
Chen YY
Medicine (Baltimore); 2017 Mar; 96(9):e5993. PubMed ID: 28248857
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms in warfarin and tacrolimus-related genes VKORC1, CYP2C9 and CYP3A5 in the Greek-Cypriot population.
Hadjipanagi D; Chrysanthou S; Voskarides K; Deltas C
BMC Res Notes; 2014 Mar; 7():123. PubMed ID: 24593903
[TBL] [Abstract][Full Text] [Related]
17. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
[TBL] [Abstract][Full Text] [Related]
18. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
[TBL] [Abstract][Full Text] [Related]
20. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
